Chemoradiotherapy Clinical Trial
Official title:
A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients
Verified date | October 2022 |
Source | China Medical University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical trial is to learn about the clinical efficacy of San-Zhong-Kui-Jian-Tang (SZKJT), a formula of Chinese medicine in head and neck cancer patients receiving concurrent chemoradiotherapy (CCRT) treatments. The main questions it aims to answer are: - Can SZKJT improve the completion rate of CCRT? - Can SZKJT reduce the adverse effects of CCRT? - How SZKJT affect the quality of life in the patients receiving CCRT - How about the safety of using SZKJT in the patients receiving CCRT Participants will be asked to: - take SZKJT for 9 weeks during the whole CCRT course - take questionnaires of quality of life
Status | Completed |
Enrollment | 21 |
Est. completion date | December 25, 2020 |
Est. primary completion date | June 14, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 65 Years |
Eligibility | Inclusion Criteria: - aged from 20- to 65-year-old; - firstly diagnosed as head and neck cancer with stage II, III or IV; - adjuvant therapy with chemotherapy of Cisplatin or combined with radiotherapy after surgery; - or chemotherapy of Cisplatin for those without surgery; - wiliness to sign inform consent. Exclusion Criteria: - pregnancy; - non-Squamous-cell carcinoma; - secondary cancer or Carcinoma in situ in 5 years; - any evidence of metastasis; - abnormality of liver, kidney or bone marrow functions before treatments; - unstable vital signs; - episode of acute infection; - unclear consciousness for inform consent; - receiving other herbal, complementary or acupuncture therapy. |
Country | Name | City | State |
---|---|---|---|
Taiwan | China Medical University Hospital | Taichung |
Lead Sponsor | Collaborator |
---|---|
China Medical University Hospital |
Taiwan,
Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003 Jan 1;21(1):92-8. — View Citation
Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefèbvre JL. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005 Oct;27(10):843-50. — View Citation
Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004 May 6;350(19):1945-52. — View Citation
Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK; Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004 May 6;350(19):1937-44. — View Citation
Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1198-205. doi: 10.1016/j.ijrobp.2012.05.008. Epub 2012 Jun 30. — View Citation
Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003 Nov 27;349(22):2091-8. — View Citation
Groome PA, O'Sullivan B, Mackillop WJ, Jackson LD, Schulze K, Irish JC, Warde PR, Schneider KM, Mackenzie RG, Hodson DI, Hammond JA, Gulavita SP, Eapen LJ, Dixon PF, Bissett RJ. Compromised local control due to treatment interruptions and late treatment breaks in early glottic cancer: Population-based outcomes study supporting need for intensified treatment schedules. Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1002-12. Epub 2006 Jan 18. — View Citation
Herrmann T, Jakubek A, Trott KR. The importance of the timing of a gap in radiotherapy of squamous cell carcinomas of the head and neck. Strahlenther Onkol. 1994 Sep;170(9):545-9. — View Citation
Robertson AG, Robertson C, Perone C, Clarke K, Dewar J, Elia MH, Hurman D, MacDougall RH, Yosef HM. Effect of gap length and position on results of treatment of cancer of the larynx in Scotland by radiotherapy: a linear quadratic analysis. Radiother Oncol. 1998 Aug;48(2):165-73. — View Citation
Robertson C, Robertson AG, Hendry JH, Roberts SA, Slevin NJ, Duncan WB, MacDougall RH, Kerr GR, O'Sullivan B, Keane TJ. Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):319-29. — View Citation
Russo G, Haddad R, Posner M, Machtay M. Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist. 2008 Aug;13(8):886-98. doi: 10.1634/theoncologist.2008-0024. Epub 2008 Aug 13. Review. — View Citation
Suwinski R, Sowa A, Rutkowski T, Wydmanski J, Tarnawski R, Maciejewski B. Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):399-412. — View Citation
Thomas K, Martin T, Gao A, Ahn C, Wilhelm H, Schwartz DL. Interruptions of Head and Neck Radiotherapy Across Insured and Indigent Patient Populations. J Oncol Pract. 2017 Apr;13(4):e319-e328. doi: 10.1200/JOP.2016.017863. Epub 2017 Mar 7. Erratum in: J Oncol Pract. 2017 Jul;13(7):466. — View Citation
Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003 Mar;66(3):253-62. Review. — View Citation
* Note: There are 14 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The completion rate | We counted the percentage rate of those who achieved and did not reach the CCRT course. | We will do an assessment at the seventh week of CCRT. Patients who had completed a seven-week course of treatment and had a cumulative dose of cisplatin greater than 200 mg per m2 will be considered the completion group. | |
Secondary | The adverse effects | We apply Common Terminology Criteria for Adverse Events (CTCAE) to assess the adverse effects of CCRT. | The assessment is performed at the eighth week. | |
Secondary | The change in Quality of Life | We assess the patients' quality of life by using the European Organisation for Research and Treatment of Cancer (EORTC) quality-of-life questionnaire QLQ-C30. | The questionnaire is assessed at the baseline and the eighth week. | |
Secondary | The Change of Constitutions of traditional Chinese medicine | We assess the patients' constitutions of traditional Chinese medicine by using Body Constitution Questionnaire (BCQ). | The questionnaire is assessed at the baseline and the eighth week. | |
Secondary | The change of liver function | We monitor the liver function of the patients by blood chemistry analysis. The levels of Alanine transaminase (ALT) and Aspartate transaminase (AST) are recorded as units per liter. | The lab data of biochemistry analysis is collected at the baseline and the eighth week. | |
Secondary | The change of renal function | We monitor the renal function of the patients by blood chemistry analysis. The levels of blood urine nitrogen (mg/dL) and creatinine (mg/dL) are recorded. Glomerular filtration rate (GFR) is estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine Equation (2021). | The lab data of biochemistry analysis is collected at the baseline and the eighth week. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05161572 -
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT02399306 -
Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma
|
Phase 3 | |
Recruiting |
NCT03286348 -
Analysis of Nutrition During Chemoradiotherapy in Patients With Gastrointestinal Cancer
|
N/A | |
Recruiting |
NCT04821765 -
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
|
Phase 2 | |
Recruiting |
NCT04278287 -
Chemoradiotherapy in Unresectable Esophageal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05863260 -
Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer
|
||
Active, not recruiting |
NCT05027165 -
Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
|
||
Completed |
NCT04207918 -
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
|
Phase 2 | |
Recruiting |
NCT06219083 -
Nutrition and Cancer Outcomes in Shaanxi Chemoradiotherapy
|
||
Active, not recruiting |
NCT04764227 -
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
|
Phase 2 | |
Recruiting |
NCT06421376 -
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
|
Phase 2 | |
Recruiting |
NCT05311566 -
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05286086 -
Prehabilitation in Rectal Cancer: During Neoadjuvant Therapy vs Preoperative
|
N/A | |
Recruiting |
NCT04772001 -
Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer
|
N/A | |
Recruiting |
NCT06410651 -
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT06429839 -
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
|
Phase 2 | |
Recruiting |
NCT03177382 -
Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors
|
Phase 3 | |
Not yet recruiting |
NCT06413342 -
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT00973778 -
A Study for Short Preoperative Chemoradiotherapy for Resectable Rectal Carcinoma
|
Phase 2 | |
Recruiting |
NCT06190847 -
Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer
|